A Randomized Double-Blind, Placebo-controlled Dose Escalating Study of the Pharmacokinetics, Safety and Tolerability of Testosterone Undecanoate (ABT-SLV361) in Hypogonadal Males.

Trial Profile

A Randomized Double-Blind, Placebo-controlled Dose Escalating Study of the Pharmacokinetics, Safety and Tolerability of Testosterone Undecanoate (ABT-SLV361) in Hypogonadal Males.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2011

At a glance

  • Drugs Testosterone undecanoate (Primary)
  • Indications Hypogonadism
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 02 Nov 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 02 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Aug 2011 Planned end date changed from Jul 2011 to Sep 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top